AUSTIN, Texas, Sept. 16, 2021 /PRNewswire/ -- Advances in
DNA/RNA sequencing promise to revolutionize how medical communities
identify, detect, and treat diseases and manage public health
threats. To make this technology more accessible and increase its
impact, Oracle has teamed up with Oxford Nanopore Technologies, the
company behind a new generation of high-performance, rapid,
scalable, and accessible sequencing technology.
Oracle and Oxford Nanopore have recently begun a collaboration
to jointly explore several potential new solutions that would use
genomic sequencing running on Oracle Cloud
Infrastructure (OCI) to help speed medical breakthroughs and
improve patient care.
Scientific researchers in more than 100 countries are already
using nanopore sequencing to further their understanding of biology
in a range of areas including human and cancer genetics as well as
plant, animal, and environmental analyses. In addition, nanopore
sequencing has been used for pathogen analysis, including the
outbreak surveillance of tuberculosis, food-borne pathogens,
Ebola, Zika, Lassa fever, dengue fever, influenza, and most
recently COVID-19.
As part of the collaboration, Oxford Nanopore will be using
OCI in applied and clinical markets. Leveraging the high
performance, security, and extensive reach of Oracle Cloud, Oracle
and Oxford Nanopore will have the ability to extend
population-scale genetic sequencing across the globe.
The organizations will also take on several ambitious projects
spanning epidemiology, whole-genome sequencing, and healthcare and
drug discovery. This includes integrating Oxford Nanopore's DNA/RNA
sequencing capabilities and data into Oracle's broad portfolio of
healthcare and life sciences applications to strengthen the
links between genomics, medical treatment, and drug
development.
"Oxford Nanopore's innovative sequencing technology is
unparalleled in the market for its ability to generate rich,
accurate genomic data at any scale, from handheld devices to
ultra-high output installations," said Mike
Sicilia, executive vice president of Oracle Vertical
Industries. "By integrating genomic data into our existing
applications and cloud infrastructure solutions, we can get these
powerful tools into the hands of more people to solve critical
health issues faster and improve patient outcomes to usher in a new
era of genomic breakthrough."
In parallel, Oracle has committed to investing £150 million in
Oxford Nanopore, subject to customary conditions.
About Oracle
Oracle offers integrated suites of
applications plus secure, autonomous infrastructure in the Oracle
Cloud. For more information about Oracle (NYSE: ORCL), please
visit us at oracle.com.
Trademarks
Oracle, Java, and MySQL are registered
trademarks of Oracle Corporation.
"Safe Harbor" Statement
This press release contains
forward-looking statements including, among other things,
statements relating to (1) a memorandum of understanding between
Oracle and Oxford Nanopore Technologies, whereby the two companies
will explore collaboratively a number of potential new solutions to
address opportunities in applied and clinical markets and related
go-to-market strategies, including Oxford Nanopore Technologies'
migration of its EPI2ME platform to the Oracle Cloud Infrastructure
and (2) Oracle's commitment to invest $150
million in Oxford Nanopore Technologies. These
forward-looking statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995.
The degree to which the parties collaborate, the migration of the
platform and the success of the foregoing, as well as the
consummation of the investment, are subject to many factors that
could cause actual results to differ materially. A detailed
discussion of these factors and other risks that affect our
business is contained in our SEC filings, including our most recent
reports on Form 10-K and Form 10-Q, particularly under the heading
"Risk Factors." All information set forth in this press release is
current as of September [13], 2021. Oracle undertakes no duty to
update any statement in light of new information or future
events.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/oracle-and-oxford-nanopore-team-up-to-improve-healthcare-and-speed-discovery-of-new-medical-breakthroughs-301378279.html
SOURCE Oracle